Elpiscience is a clinical-stage biopharmaceutical company developing next-generation cancer immunotherapies using proprietary monoclonal and bispecific antibody technologies. The company aims to improve treatment outcomes for cancer patients by advancing targeted therapies that engage the immune system to eliminate tumors.
Funding
$105M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
GBFounders
Product
Problem
Cancer immunotherapies face challenges in effectively targeting tumors and stimulating the immune system to eliminate them, resulting in limited treatment outcomes for many cancer patients. Current approaches may lack specificity, fail to fully engage the immune response, or encounter resistance mechanisms within the tumor microenvironment.
Solution
Elpiscience is developing next-generation cancer immunotherapies using proprietary monoclonal and bispecific antibody technologies to improve treatment outcomes for cancer patients. Their approach focuses on advancing targeted therapies that engage the immune system to eliminate tumors. Elpiscience leverages internal R&D capabilities, including antibody discovery, translational research, and clinical development, to advance innovative programs. They also collaborate with global biopharmaceutical companies, academic institutions, and clinicians to accelerate the development of these immunotherapies.
Target Audience
The primary target audience includes cancer patients, oncologists, and biopharmaceutical companies seeking innovative cancer immunotherapies.
Features
- Proprietary monoclonal and bispecific antibody discovery platform
- Focus on immuno-oncology targets
- Translational research capabilities
- Clinical development expertise
- Pipeline of globally innovative cancer immunotherapies
- Bispecific Macrophage Engager (BiME®) technology